Chemicals are a critical, but often overlooked, factor of success for a circular economy. 96% of all products on European markets, from food to medical treatments, from buildings to consumer electronics, rely on chemicals, so this shouldn’t come as a surprise. But what does circularity mean for the future of the chemicals industry? Should it embrace circular systems or resist them?
Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.
So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.
DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.
China`s 14th Five-Year Plan (FYP) covering the period from 2021 to 2025 will only be published after its acceptance by the National People`s Congress in March 2021.
We are in the midst of a start-up revolution. The growth of innovation-driven start-up activity is profound and global in scope, and it is a driving force of change even in mature industries such as the chemical and pharmaceutical sector.
Linde intends to further expand its hydrogen business by investing in electrolysis capacities and infrastructure.
Why BASF Venture Capital is investing in SmartAHC, a supplier of digitalization solutions for pig farming on the Chinese market.
The WeylChem Group of companies consists of seven operating and two R&D sites in Europe and the USA as well as the global sales and marketing platform, WeylChem International.
The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.
Virtual Prototyping of Complex Fluids and Flowing Materials
The shift to a circular economy requires intensive cooperation along the chemical value chain and across industries.
Like most industries, the global chemical industry is currently strongly affected by the outbreak of Covid-19.
In 2019, the pharmaceutical industry invested $182 billion in drug development, but only 48 drugs were approved for use.
The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.
As customers engage in more multi-channel interactions, having a deep understanding of these journeys is an essential component for the customer service function, and for ensuring excellence in the overall customer experience.
Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.
